Article

Ocriplasmin gets FDA advisory committee meeting

ThromboGenics NV has been notified by the FDA that its new biologic license application (BLA) for ocriplasmin intravitreal injection will be discussed by the Dermatologic and Ophthalmic Drugs Advisory Committee on July 26.

Leuven, Belgium-ThromboGenics NV has been notified by the FDA that its new biologic license application (BLA) for ocriplasmin intravitreal injection will be discussed by the Dermatologic and Ophthalmic Drugs Advisory Committee on July 26.

Ocriplasmin is an investigational biological drug candidate intended for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole. ThromboGenics resubmitted its BLA for ocriplasmin in April in anticipation of it being granted priority review by the FDA.

Ocriplasmin has successfully completed two phase III clinical trials for the pharmacological treatment of symptomatic VMA, including macular hole. In addition to the BLA being resubmitted in the United States, the marketing authorization application for ocriplasmin has been accepted for review in Europe. The drug is in phase II clinical development for additional vitreoretinal conditions.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.